The Latest Cardiac and Vascular News
VALOR-HCM Designed to Generate Direct Evidence of Improved Outcomes for People with HCM by Reducing the Need for Invasive Septal Reduction Therapy BRISBANE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) — In a release issued under the same headline on Monday, August 3rd by MyoKardia, Inc. (Nasdaq: MYOK), please note that the second quote by Jeffrey B. […]
BOZEMAN, Mont., July 31, 2020 /PRNewswire/ — Pulsara, the leading telehealth and communication platform that connects teams across organizations, announced today that the company has been named a compatible vendor within the American Heart Association Get With The Guidelines® program. This premier AHA program assists hospitals in measuring and improving cardiovascular disease and […]
Study conducted at 109 hospitals with oversight by 10 Japanese professional societies, including Japanese Circulation Society TOKYO–(BUSINESS WIRE)–A three-year, investigator-led, prospective study of Japanese patients who received an Impella heart pump finds use of Impella is associated with a 77% survival rate at 30 days in AMI cardiogenic shock patients. The historic […]
– Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction – Treatment of heart failure is an important unmet need with over half of those diagnosed dying within five […]
HITRUST CSF Certification validates Ontrak is committed to meeting key regulations and protecting sensitive information SANTA MONICA, Calif.–(BUSINESS WIRE)–Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that the company’s data pipeline system, eOntrak Case Management System and supporting technology infrastructure have […]
EDEN PRAIRIE, Minn., July 30, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS) today announced the signing of a distribution agreement with SysteMedic Ltd., covering Israel and Palestine, representing the second distribution partnership in the Middle East region. Ultrafiltration therapy is now available in 16 countries outside the U.S. Ninety […]
– Jardiance (empagliflozin) significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction – Treatment of heart failure is an important unmet need with over half of those diagnosed […]
HANGZHOU, China, July 29, 2020 /PRNewswire/ — On July 23, 2020, Professor Jian’an Wang’s team at the Second Affiliated Hospital of Zhejiang University School of Medicine successfully completed the world’s first human clinical application of the transcatheter mitral valve repair system (DragonFly™) developed by Hangzhou Valgen Medtech Co.,Ltd. This marks a major breakthrough […]
TAMPA, Fla., July 29, 2020 /PRNewswire/ — Keystone Heart, LTD., a medical device innovator driven to redefine the standard of structural heart care, today announced completion of the first worldwide commercial case using the TriGUARD 3™ Cerebral Embolic Protection (CEP) Device. Pieter Stella, MD, Assistant Professor, Medical Department of Cardiology, at UMC Utrecht in the […]
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a Phase 2 clinical study. The study is evaluating the efficacy, safety, and tolerability […]
